Drug intelligence / Profile preview

brivaracetam + levetiracetam

Development stage: Unknown
Lead developer: UCB
Modality: Small Molecules
Administration: Intravenous

Overview

This entry refers to the comparative study of brivaracetam and levetiracetam, two antiseizure medications that target the synaptic vesicle glycoprotein 2A (SV2A). Brivaracetam is a high-affinity SV2A ligand with greater lipophilicity than its predecessor, levetiracetam. The specific context provided involves a randomized, double-blind, crossover clinical trial (NCT03580707) led by William E. Rosenfeld, M.D., which evaluated the speed of onset and pharmacodynamic effects of these drugs in patients with photosensitive epilepsy. The study utilized the suppression of the photoparoxysmal response (PPR) on EEG as a marker for central nervous system activity to determine if brivaracetam's higher affinity and lipophilicity result in a faster clinical effect compared to levetiracetam.

Brand names: BriviactKeppra
Other names: BRVLEV

Targets

SV2A (Synaptic vesicle glycoprotein 2A)

Beyond the preview

Go deeper on brivaracetam + levetiracetam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on brivaracetam + levetiracetam.

Explore the full profile